Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
            <i>Enterobacterales</i>
            Isolates

Teo, Jin Yao; Chang, Hong Yi; Tan, Si Hui; Tang, Cheng Yee; Ong, Rick Twee‐Hee; Ko, Karrie Kwan Ki; Chung, Shimin Jasmine; Tan, Thuan Tong; Kwa, Andrea Lay-Hoon

doi:10.1128/spectrum.01002-23

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If we interpret these values by EUCAST breakpoints (for E. coli, ≤0.5 mg/L susceptible category) [17], only three isolates can be determined to be susceptible, which indicates the need to harmonize breakpoints between the two standards. Our results were similar to the results obtained in Singapore (89.6% susceptibility with FDA criteria) [48] and Greece (80.5% susceptibility rate) [30]. The EUCAST breakpoints for E. coli are supposed to be more relevant, as some researchers reported therapeutic success if MICs were below 0.5 mg/L [4,49].…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics against Carbapenemase-Producing Enterobacteria—A Pilot Study in Bulgaria

Markovska,

Stankova,

Stoeva

et al. 2024

Antibiotics

View full text Add to dashboard Cite

To solve the problem with pan-drug resistant and extensively drug-resistant Gram-negative microbes, newly approved drugs such as ceftazidime/avibactam, cefiderocol, plazomicin, meropenem/vaborbactam, and eravacycline have been introduced in practice. The aim of the present study was to collect carbapenemase-producing clinical Enterobacterales isolates, to characterize their carbapenemase genes and clonal relatedness, and to detect their susceptibility to commonly used antimicrobials and the above-mentioned newly approved antibiotics. Sixty-four carbapenemase producers were collected in a period of one year from four Bulgarian hospitals, mainly including Klebsiella pneumoniae (89% of the isolates) and also single Proteus mirabilis, Providencia stuartii and Citrobacter freundii isolates. The main genotype was blaNDM-1 (in 61%), followed by blaKPC-2 (23%), blaVIM-1 (7.8%) and blaOXA-48 (7.8%). Many isolates showed the presence of ESBL (blaCTX-M-15/-3 in 76.6%) and AmpC (blaCMY-4 in 37.5% or blaCMY-99 in 7.8% of isolates). The most common MLST type was K. pneumoniae ST11 (57.8%), followed by ST340 (12.5%), ST258 (6.3%) and ST101 (6.3%). The isolates were highly resistant to standard-group antibiotics, except they were susceptible to tigecycline (83.1%), colistin (79.7%), fosfomycin (32.8%), and aminoglycosides (20.3–35.9%). Among the newly approved compounds, plazomicin (90.6%) and eravacycline (76.3%) showed the best activity. Susceptibility to ceftazidime/avibactam and meropenem/vaborbactam was 34.4% and 27.6%, respectively. For cefiderocol, a large discrepancy was observed between the percentages of susceptible isolates according to EUCAST susceptibility breakpoints (37.5%) and those of CLSI (71.8%), detected by the disk diffusion method. This study is the first report to show patterns of susceptibility to five newly approved antibiotics among molecularly characterized isolates in Bulgaria. The data may contribute to both the improvement of treatment of individual patients and the choice of infection control strategy and antibiotic policy.

show abstract

Section: Discussionsupporting

confidence: 89%

“…Other authors have also reported similar findings. Teo et al reported 53.4% susceptibility to eravacycline and 89.6% to tigecycline [48]. Higher levels of susceptibility to tigecycline and eravacycline (89% and 85.7% respectively) have been reported by authors from China [52].…”

Section: Discussionmentioning

confidence: 95%

In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics against Carbapenemase-Producing Enterobacteria—A Pilot Study in Bulgaria

Markovska,

Stankova,

Stoeva

et al. 2024

Antibiotics

View full text Add to dashboard Cite

show abstract

Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance

Laxminarayan,

Impalli,

Rangarajan

et al. 2024

The Lancet

View full text Add to dashboard Cite

Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications

Huang,

Hsu,

Tang

et al. 2024

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Enterobacterales Isolates

Abstract: This study determined the susceptibilities of carbapenem-resistant Enterobacterales isolates to various novel antimicrobial agents (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, eravacycline, and plazomicin). Whole-genome sequencing was performed for all strains.

Cited by 4 publications

References 21 publications

In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics against Carbapenemase-Producing Enterobacteria—A Pilot Study in Bulgaria

In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics against Carbapenemase-Producing Enterobacteria—A Pilot Study in Bulgaria

Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance

Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications

Contact Info

Product

Resources

About